AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6225508 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C and 5‐FU (MF)
Number of subjects: 116
Study 31992495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg)
Number of subjects: 100
Study 31992495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31034251 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-W (daily consumption of margarine containing 2 g/day of plant sterols with 30-min daily walking)
Number of subjects: 15
Study 31034251 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-W
Number of subjects: 15
Study 31034251 — intervention group
Group type: COMPARATOR
Intervention: C-S (daily consumption of control margarine while sedentary)
Number of subjects: 15
Study 31034251 — intervention group
Group type: COMPARATOR
Intervention: PS-S (daily consumption of margarine containing 2 g/day of plant sterols while sedentary)
Number of subjects: 15
Study 31034251 — intervention group
Group type: COMPARATOR
Intervention: C-W (daily consumption of control margarine with 30-min daily walking)
Number of subjects: 15
Study 28544241 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-α-tocopherol supplementation (400 IU single dose)
Number of subjects: 50
Study 26592221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method (PG)
Number of subjects: 22
Study 26592221 — intervention group
Group type: COMPARATOR
Intervention: General exercise (GEG)
Number of subjects: 22
Study 23937010 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol Standardized Enteric Coated Soft Capsules, 0.3 g, 3 times a day, for 3 months
Number of subjects: 60
Study 23937010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 23937010 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol Standardized Enteric Coated Soft Capsules
Number of subjects: 60
Study 21398682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IVAC educational methodology)
Number of subjects: 0
Study 21398682 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19858871 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during surgery (pure tones via headphones)
Number of subjects: 87
Study 19858871 — intervention group
Group type: COMPARATOR
Intervention: No auditory stimulation (control group)
Number of subjects: 87
Study 19858871 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (induced with thiopental and maintained with fentanyl and sevoflurane)
Number of subjects: 87
Study 17031646 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐547,632 plus paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Number of subjects: 70
Study 17031646 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐547,632 plus chemotherapy
Number of subjects: 70
Study 17031646 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and carboplatin)
Number of subjects: 70
Study 14615471 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (50 mg, 100 mg, 200 mg twice daily and 200 mg thrice daily)
Number of subjects: 32
Study 14615471 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Number of subjects: 32
Study 14615471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10754780 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation (2 mg two times daily) from the early proliferative phase to the late secretory phase of the endometrium
Number of subjects: 81
Study 10754780 — intervention group
Group type: COMPARATOR
Intervention: No E2 supplementation (control group)
Number of subjects: 81
Study 10754780 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation (2 mg two times daily)
Number of subjects: 81
Study 9105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressives
Number of subjects: 257
Study 9105958 — intervention group
Group type: COMPARATOR
Intervention: Bipolar patients
Number of subjects: 257
Study 9105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathology
Number of subjects: 257
Study 1541787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental dietary formula (amino acid)
Number of subjects: 30
Study 1541787 — intervention group
Group type: COMPARATOR
Intervention: Polymeric dietary formula (intact protein isolates)
Number of subjects: 30
Study 3872835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (7.5 mg)
Number of subjects: 30
Study 3872835 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (16 mg)
Number of subjects: 30
Study 28961380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (magnetic stimulation)
Number of subjects: 39
Study 28961380 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 39
Study 27924392 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stenting as a bridge to surgery (SBTS)
Number of subjects: 115
Study 27924392 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery (ES)
Number of subjects: 115
Study 26100611 — intervention group
Group type: EXPERIMENTAL
Intervention: HORIZON trauma focused cognitive behavioral therapy with parental components
Number of subjects: 100
Study 21193320 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Perimount Magna (EPM)
Number of subjects: 108
Study 21193320 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Mosaic (MM)
Number of subjects: 108
Study 19665587 — intervention group
Group type: EXPERIMENTAL
Intervention: acyclovir 400mg BD
Number of subjects: 1305
Study 19665587 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1305
Study 17884623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% POL foam
Number of subjects: 148
Study 17884623 — intervention group
Group type: COMPARATOR
Intervention: 1% POL foam
Number of subjects: 148
Study 15136099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial sampling and measurement of serum estradiol and progesterone 1 to 14 days after the midcycle urinary luteinizing hormone surge.
Number of subjects: 130
Study 15136099 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dating criteria and histologic features analysis.
Number of subjects: 130
Study 11841079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin 200 ml orally for 2 consecutive days before operation
Number of subjects: 58
Study 11841079 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution through a nasogastric tube
Number of subjects: 58
Study 10463377 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg physostigmine patch
Number of subjects: 204
Study 10463377 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg physostigmine patch
Number of subjects: 204
Study 10463377 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 204
Study 7595767 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal amino acid formulation
Number of subjects: 20
Study 7595767 — intervention group
Group type: COMPARATOR
Intervention: General-purpose intravenous amino acid solution
Number of subjects: 20
Study 2195722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine
Number of subjects: 92
Study 2195722 — intervention group
Group type: COMPARATOR
Intervention: No vincristine
Number of subjects: 92
Study 2195722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (high-risk patients)
Number of subjects: 92
Study 2195722 — intervention group
Group type: COMPARATOR
Intervention: No vincristine (high-risk patients)
Number of subjects: 92
Study 517815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluent
Number of subjects: 3
Study 517815 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 3
Study 517815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 517815 — intervention group
Group type: COMPARATOR
Intervention: Time
Number of subjects: 3
Study 517815 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 3
Study 31613877 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented bladder diverticulum (BD)
Number of subjects: 10662
Study 31613877 — intervention group
Group type: COMPARATOR
Intervention: Non-BD subjects (comparison cohort)
Number of subjects: 10662
Study 28202013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based sequential treatment (10-day regimen: Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg bid/tid for the following 5 days)
Number of subjects: 200
Study 28202013 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-based sequential treatment (10-day modified regimen with Levofloxacin 500 mg id instead of Clarithromycin)
Number of subjects: 200
Study 26004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5mg the night before surgery
Number of subjects: 478
Study 26004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg the morning of surgery
Number of subjects: 478
Study 26004882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 22799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction treatment (Group 1)
Number of subjects: 269
Study 22799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextraction treatment (Group 2)
Number of subjects: 269
Study 22799528 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Group 3)
Number of subjects: 269
Study 21492764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 17802
Study 21492764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 21492764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily (without LDL-C <50 mg/dl)
Number of subjects: 17802
Study 19699857 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 x 10(6) BMMNCs on day 3 post-AMI
Number of subjects: 120
Study 19699857 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 x 10(6) BMMNCs on day 7 post-AMI
Number of subjects: 120
Study 19699857 — intervention group
Group type: COMPARATOR
Intervention: Placebo on day 3 post-AMI
Number of subjects: 120
Study 19699857 — intervention group
Group type: COMPARATOR
Intervention: Placebo on day 7 post-AMI
Number of subjects: 120
Study 17129389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriatic drops (Tropicamide 1%, Phenylephrine 2.5%, Diclofenac sodium 0.1%)
Number of subjects: 130
Study 17129389 — intervention group
Group type: COMPARATOR
Intervention: Depot method (wick soaked in the same drop mixture)
Number of subjects: 130
Study 12594144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 5% (Group T, n=30)
Number of subjects: 60
Study 12594144 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 2% (Group P, n=30)
Number of subjects: 60
Study 11212860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona thinning (ZT) using a laser diode with 1.48‐micron wavelength (Fertilaser)
Number of subjects: 103
Study 11212860 — intervention group
Group type: COMPARATOR
Intervention: No zona thinning (Control group)
Number of subjects: 103
Study 8889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO) 80 mg x 2/day for 7 days
Number of subjects: 7
Study 8889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PIN) 10 mg x 2/day for 7 days
Number of subjects: 7
Study 8889317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 1824585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.5 mg/kg)
Number of subjects: 97
Study 1824585 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.04 mg/kg)
Number of subjects: 97
Study 1824585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 97
Study 1824585 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 97
Study 6407438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 or 360 mg/day
Number of subjects: 42
Study 2883817 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam (20 mg/day)
Number of subjects: 100
Study 2883817 — intervention group
Group type: COMPARATOR
Intervention: flunitrazepam (2 mg/day)
Number of subjects: 100
Study 29084042 — intervention group
Group type: EXPERIMENTAL
Intervention: Local drug delivery of abciximab (IL, by the ClearWay catheter) plus aspiration thrombectomy (AT)
Number of subjects: 59
Study 29084042 — intervention group
Group type: COMPARATOR
Intervention: Nonlocal drug delivery of abciximab (IC, by the guide catheter) plus aspiration thrombectomy (AT)
Number of subjects: 59
Study 26971071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for psychosis based Guided Self-help (CBTp-GSH)
Number of subjects: 33
Study 26971071 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 33
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial electromechanical interval (AEMI)
Number of subjects: 108
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index (LAVI)
Number of subjects: 108
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak myocardial velocity during late diastole (a')
Number of subjects: 108
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: AEMI
Number of subjects: 108
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, use of antiarrhythmic drugs, and AEMI
Number of subjects: 108
Study 23906195 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVI and a'
Number of subjects: 108
Study 23906195 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 108
Study 22252094 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine+clinical management (IMI‐CM)
Number of subjects: 250
Study 22252094 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐Behavioral Therapy (CBT)
Number of subjects: 250
Study 22252094 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 250
Study 22252094 — intervention group
Group type: COMPARATOR
Intervention: pill placebo (PLA‐CM)
Number of subjects: 250
Study 20235065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid hip resurfacing (HR)
Number of subjects: 209
Study 20235065 — intervention group
Group type: COMPARATOR
Intervention: 28 mm total hip arthroplasty (THA)
Number of subjects: 209
Study 18322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic absorption
Number of subjects: 0
Study 18322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric distress
Number of subjects: 0
Study 16124422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg/day of artesunate for 3 days and 3 daily doses of 8.0 mg/kg/day mefloquine
Number of subjects: 120
Study 16124422 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg/day of artesunate for 3 days and mefloquine given as 15 mg/kg on the first day and 10 mg/kg on the second day
Number of subjects: 120
Study 14506624 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 66
Study 14506624 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 66
Study 11018188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 105
Study 11018188 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 105
Study 9479799 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone prompt by a non-medical research assistant
Number of subjects: 364
Study 9479799 — intervention group
Group type: COMPARATOR
Intervention: Conventional mail-outs (Control)
Number of subjects: 364
Study 1832344 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 99-126 3 pmol/kg/min
Number of subjects: 33
Study 1832344 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 99-126 10 pmol/kg/min
Number of subjects: 33
Study 1832344 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 103-126 3 pmol/kg/min
Number of subjects: 33
Study 1832344 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 103-126 10 pmol/kg/min
Number of subjects: 33
Study 1832344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% D-glucose)
Number of subjects: 33
Study 6342784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (600 mg daily)
Number of subjects: 30
Study 6342784 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg daily)
Number of subjects: 30
Study 30969201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal 5 mg
Number of subjects: 589
Study 30969201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal 10 mg
Number of subjects: 589
Study 30969201 — intervention group
Group type: COMPARATOR
Intervention: Ulipristal 5 mg and 10 mg
Number of subjects: 589
Study 30255637 — intervention group
Group type: EXPERIMENTAL
Intervention: Play activities program (1 hour weekly for 8 weeks)
Number of subjects: 53
Study 30255637 — intervention group
Group type: COMPARATOR
Intervention: Reading books and magazines (15 minutes weekly for 8 weeks)
Number of subjects: 53
Study 27247219 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR(BC) program (6 weeks)
Number of subjects: 322
Study 27247219 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 322
Study 24878457 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendectomy (within 24 hours of diagnosis)
Number of subjects: 195
Study 24878457 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendectomy
Number of subjects: 195
Study 24878457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval appendectomy (4-6 weeks after initial treatment with antibiotics)
Number of subjects: 195
Study 24878457 — intervention group
Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 195
Study 23076197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 40
Study 23076197 — intervention group
Group type: COMPARATOR
Intervention: Control (no ulinastatin)
Number of subjects: 40
Study 20658820 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat invalid trials (smokers)
Number of subjects: 29
Study 20658820 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat valid trials (smokers and nonsmokers)
Number of subjects: 29
Study 20658820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time measures
Number of subjects: 29
Study 18321181 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase smoking cessation (n = 25)
Number of subjects: 44
Study 18321181 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase smoking cessation (n = 19)
Number of subjects: 44
Study 18321181 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population (n = 35 who initiated treatment)
Number of subjects: 44
Study 15557136 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm CO inhalation for 1 hour
Number of subjects: 0
Study 15557136 — intervention group
Group type: COMPARATOR
Intervention: Synthetic air (placebo) inhalation
Number of subjects: 0
Study 12218381 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose estrogen plus methyltestosterone
Number of subjects: 0
Study 12218381 — intervention group
Group type: COMPARATOR
Intervention: High-dose estrogen
Number of subjects: 0
Study 10809858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed blue and red light (415 and 660 nm)
Number of subjects: 107
Study 10809858 — intervention group
Group type: COMPARATOR
Intervention: Blue light (415 nm)
Number of subjects: 107
Study 10809858 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide cream
Number of subjects: 107
Study 10809858 — intervention group
Group type: COMPARATOR
Intervention: Cool white light
Number of subjects: 107
Study 8874253 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of i.v. antibiotics followed by 8 days of oral therapy
Number of subjects: 75
Study 8874253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of i.v. antibiotics followed by 5 days of oral therapy
Number of subjects: 75
Study 8874253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of i.v. antibiotics
Number of subjects: 75
Study 8874253 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 75
Study 1686784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg once a day, at 0700 h)
Number of subjects: 10
Study 6390331 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling parents on more effective responses to infant crying
Number of subjects: 60
Study 6390331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 31492179 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort
Number of subjects: 1479
Study 31492179 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT
Number of subjects: 1479
Study 31492179 — intervention group
Group type: COMPARATOR
Intervention: High-flow oxygen therapy
Number of subjects: 1479
Study 29882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg
Number of subjects: 20
Study 29882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 1.0 mg
Number of subjects: 20
Study 29882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2.0 mg
Number of subjects: 20
Study 29882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2.0 mg and Riociguat 0.5 mg
Number of subjects: 20
Study 29882087 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2.0 mg and Riociguat 1.0 mg
Number of subjects: 20
Study 29882087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29798272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscopic surgery
Number of subjects: 82
Study 29798272 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (radiotherapy)
Number of subjects: 82
Study 24878142 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDO programme
Number of subjects: 84
Study 24878142 — intervention group
Group type: COMPARATOR
Intervention: CAU (Care as Usual)
Number of subjects: 84
Study 23075703 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono‐LPV/r)
Number of subjects: 195
Study 23075703 — intervention group
Group type: COMPARATOR
Intervention: tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r)
Number of subjects: 195
Study 23075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TWAUC HIV RNA between mono‐LPV/r and TDF/3TC/LPV/r
Number of subjects: 195